| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $82,940,078 ) (Continued on the next page) |
| | 2025 | 2025 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | U01CA294811 | Implementing Sustainable mobile health Technology to Optimize smoking cessation Program for Lao people with HIV (I-STOP) | 000 | 2 | NIH | 8/27/2025 | $527,324 |
| | 2025 | 2025 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | UG1CA287044 | Oklahoma TRUST Access Hub | 003 | 2 | NIH | 7/24/2025 | $0 |
| | 2025 | 2025 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | UG1CA287044 | Oklahoma TRUST Access Hub | 002 | 2 | NIH | 5/29/2025 | $82,101 |
| | 2025 | 2025 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | UG1CA287044 | Oklahoma TRUST Access Hub | 001 | 2 | NIH | 4/14/2025 | $450,450 |
| | 2025 | 2025 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | UG1CA287044 | Oklahoma TRUST Access Hub | 000 | 2 | NIH | 12/5/2024 | $738,924 |
| | 2025 | 2025 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | R21MD019345 | Ecological momentary assessment of daily minority stressors and cannabis and tobacco co-use among sexual minority young adults | 003 | 2 | NIH | 7/14/2025 | $181,089 |
| | 2025 | 2025 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | R01EY034133 | Correction of diabetic retinopathy by mitochondrial transfer | 001 | 3 | NIH | 4/2/2025 | $554,407 |
| | 2025 | 2025 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | R01AG083950 | Therapeutic Potential of FGF21 for Alzheimer's Disease | 003 | 3 | NIH | 5/2/2025 | $269,870 |
| | 2025 | 2025 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | R01AG083950 | Therapeutic Potential of FGF21 for Alzheimer's Disease | 000 | 3 | NIH | 4/18/2025 | $488,913 |
| | 2025 | 2025 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | R01AI185203 | Targeting chondroitin sulfate proteoglycan 4 (CSPG4) expression as a Clostridioides difficile therapeutic | 000 | 2 | NIH | 4/14/2025 | $357,500 |
| | 2025 | 2025 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | R01AG083950 | Therapeutic Potential of FGF21 for Alzheimer's Disease | 004 | 3 | NIH | 7/16/2025 | $43,459 |
| | 2025 | 2025 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | R01DK131064 | Sulfur Amino Acid Metabolism and Regulation of Hepatic Metabolic Flexibility | 000 | 4 | NIH | 12/13/2024 | $370,911 |
| | 2025 | 2025 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | R01DK131064 | Sulfur Amino Acid Metabolism and Regulation of Hepatic Metabolic Flexibility | 001 | 4 | NIH | 6/18/2025 | $41,212 |
| | 2025 | 2025 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | D4054837 | Graduate Psychology Education Programs | 00 | 1 | HRSA | 6/12/2025 | $202,794 |
| | 2025 | 2025 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | R01HD109784 | Prevention of Necrotizing Enterocolitis | 001 | 3 | NIH | 4/14/2025 | $40,935 |
| | 2025 | 2025 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | R01HD109784 | Prevention of Necrotizing Enterocolitis | 000 | 3 | NIH | 1/24/2025 | $368,415 |
| | 2025 | 2025 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | R01DK139443 | Evaluating PQQ for preventing maternal obesity-induced fetal programming of juvenile NAFLD in Papio anubis | 000 | 2 | NIH | 3/5/2025 | $559,845 |
| | 2025 | 2025 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | R01DK139443 | Evaluating PQQ for preventing maternal obesity-induced fetal programming of juvenile NAFLD in Papio anubis | 001 | 2 | NIH | 8/4/2025 | $62,204 |
| | 2025 | 2025 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | R01HL169530 | Mechanism of F-18-fluorodeoxyglucarate accrual in myocardial injury | 000 | 2 | NIH | 4/3/2025 | $362,500 |
| | 2025 | 2025 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | U54HD113173 | Center for Indigenous Resilience, Culture, and Maternal Health Equity | 000 | 3 | NIH | 8/27/2025 | $1,432,650 |
| | 2025 | 2025 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | F31DA064398 | Effects of Neurotensin on VTA Neuron Physiology and Methamphetamine Use | 000 | 1 | NIH | 7/7/2025 | $38,696 |
| | 2025 | 2025 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | F31DA064398 | Effects of Neurotensin on VTA Neuron Physiology and Methamphetamine Use | 001 | 1 | NIH | 7/7/2025 | $0 |
| | 2025 | 2025 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | R01AG072295 | Cerebromicrovascular rejuvenation by heterochronic blood exchange | 001 | 3 | NIH | 6/26/2025 | $433,349 |
| | 2025 | 2025 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | R21EY035725 | Targeting Innate Inflammation Pathways to Treat Ocular Infections | 000 | 2 | NIH | 12/20/2024 | $217,500 |
| | 2025 | 2025 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | T3555310 | Primary Care Training and Enhancement -- Residency Training in Street Medicine | 00 | 1 | HRSA | 9/10/2025 | $218,346 |
| | 2025 | 2025 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | R50CA292022 | NCI Research Specialist (Clinician Scientist) Award for Improving Cancer Screening and Clinical Trial Enrollment | 000 | 1 | NIH | 9/10/2025 | $361,695 |
| | 2025 | 2025 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | R01AI189437 | ARID3a functions in autoimmune B cells | 000 | 1 | NIH | 9/4/2025 | $700,000 |
| | 2025 | 2025 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | R01AI189437 | ARID3a functions in autoimmune B cells | 000 | 1 | NIH | 9/4/2025 | $1,049,245 |
| | 2025 | 2025 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | K01DK144648 | The function of injury-specific macrophages in acute kidney injury | 000 | 1 | NIH | 9/3/2025 | $160,887 |
| | 2025 | 2025 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | R03AG095868 | Microvascular endothelial lipid metabolism as a target for age-related vascular cognitive impairment | 000 | 1 | NIH | 9/9/2025 | $286,000 |
| | 2025 | 2025 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | U54GM104938 | Oklahoma Shared Clinical and Translational Resources | 001 | 13 | NIH | 9/4/2025 | $3,999,999 |
| | 2025 | 2025 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | U54GM104938 | Oklahoma Shared Clinical and Translational Resources | 001 | 13 | NIH | 9/4/2025 | $357,719 |
| | 2025 | 2025 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | R21CA296216 | Combining c-Myc inhibitor and SHetA2 for cervical cancer: A promising low-to-no toxicity therapeutic strategy | 000 | 1 | NIH | 6/23/2025 | $376,490 |
| | 2025 | 2025 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | K23DA062104 | A translational evaluation of depressive symptomology and smoking cessation treatment mechanisms for just-in-time-adaptive-interventions | 000 | 1 | NIH | 8/19/2025 | $139,457 |
| | 2025 | 2025 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | R01HL173312 | How Endothelial Tetraspanins Inhibit Inflammation | 000 | 1 | NIH | 8/29/2025 | $29,981 |
| | 2025 | 2025 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | R01HL173312 | How Endothelial Tetraspanins Inhibit Inflammation | 000 | 1 | NIH | 8/29/2025 | $700,000 |
| | 2025 | 2025 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | R21AG093578 | Cell-type specific role of melanocortin 4 receptor in inflammation and cognition with aging | 000 | 1 | NIH | 5/16/2025 | $393,250 |
| | 2025 | 2025 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | R01AI187329 | Defining the interaction between adrenergic nerves and immune memory | 000 | 1 | NIH | 7/23/2025 | $555,120 |
| | 2025 | 2025 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | R01DK129656 | Understanding the metabolic pathology of pediatric obesity and NAFLD | 000 | 4 | NIH | 3/5/2025 | $503,196 |
| | 2025 | 2025 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | R01EY016077 | Dyslipidemia and Diabetic Retinopathy | 001 | 17 | NIH | 7/30/2025 | $390,876 |
| | 2025 | 2025 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | R01GM146956 | Regulation of OATP1B1 and OATP1B3 by lysine acetylation and lysine deacetylase inhibitors | 000 | 4 | NIH | 6/25/2025 | $290,000 |
| | 2025 | 2025 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | R35GM160442 | Dynamics of Fungal Stress Responses in the Host Environment | 000 | 1 | NIH | 8/7/2025 | $393,250 |
| | 2025 | 2025 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | R56EY037686 | Bacterial Cloaking Devices in Intraocular Infections | 000 | 1 | NIH | 8/25/2025 | $715,000 |
| | 2025 | 2025 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | R25CA274172 | Native American Youths Enjoy Science - YES Oklahoma | 002 | 4 | NIH | 8/21/2025 | $134,319 |
| | 2025 | 2025 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | R01DA062632 | Addiction potential, flavoring content, and substitutability of concept flavored cigarillos | 000 | 1 | NIH | 7/21/2025 | $752,701 |
| | 2025 | 2025 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | F99CA305566 | Evaluating the role of the tumor macroenvironment in cancer cachexia | 000 | 1 | NIH | 7/29/2025 | $44,158 |
| | 2025 | 2025 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | R01DK134316 | Novel Roles of Cullin-RING E3 Ligases in Liver Pathophysiology | 000 | 3 | NIH | 2/17/2025 | $353,583 |
| | 2025 | 2025 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | R25CA291599 | Cancer Undergraduate Research Experience (CURE) in Oklahoma | 000 | 1 | NIH | 7/23/2025 | $211,628 |
| | 2025 | 2025 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | R35GM158394 | RAMP-altered class B GPCR hormone binding and signaling | 000 | 1 | NIH | 8/11/2025 | $389,310 |
|
